StockVS

Integer Holdings Corporation (ITGR) Stock Analysis

Healthcare

Integer Holdings Corporation

$90.14

+$0.86 (+0.96%)

Last Updated: May 26, 2026

Price History

Analysis

Company Overview

Integer Holdings Corporation operates as a medical device contract development and manufacturing entity with a global footprint spanning the United States, Costa Rica, Puerto Rico, Ireland, and international markets. The company specializes in delivering specialized products for interventional cardiology, structural heart applications, heart failure management, peripheral vascular solutions, and neurology. This business falls within the Healthcare sector, specifically the Medical Devices industry, positioning the firm as a critical supplier of manufacturing services and contract development to the broader healthcare ecosystem. As of the latest data, the company holds a market capitalization of $2.96B, generating annual revenue of $1.85B while employing a workforce of 11000 individuals. These valuation and revenue figures indicate that Integer Holdings Corporation maintains a significant operational scale, serving as a substantial component of the medical device supply chain with a substantial installed base of employees to support its diverse portfolio of contract services.

Financial Health

The company reported revenue of $1.85B over the trailing twelve months, with a net income of $102.83M and an EBITDA of $377.19M. The substantial gap between the $1.85B in revenue and the $102.83M in net income reveals a cost structure where operating expenses and taxes consume a significant portion of gross receipts before reaching the bottom line. Free cash flow stands at $76.88M, which indicates the company generates positive cash from operations sufficient to cover capital expenditures and potentially fund internal growth initiatives or debt reduction. Profitability analysis shows a gross margin of 27.4%, an operating margin of 12.8%, and a profit margin of 5.5%, suggesting that while the manufacturing business model retains a healthy gross spread, the final profitability is impacted by high operating leverage and overhead costs. The balance sheet displays $17.16M in cash against $1.32B in debt, resulting in a debt-to-equity ratio of 75.44, which characterizes a highly leveraged position where debt obligations significantly outweigh liquid assets. Despite the high leverage, the current ratio of 3.32 suggests robust short-term liquidity, indicating that the company holds more than three times the current assets required to meet its short-term liabilities. Return on equity is 6.1% and return on assets is 4.7%, metrics that reveal moderate management effectiveness in generating returns relative to the capital employed and the total asset base.

Valuation Assessment

The stock trades with a trailing P/E ratio of 29.19 and a forward P/E of 11.68, implying that the market expects a significant acceleration in earnings performance relative to historical levels. The price-to-book ratio is 1.66, indicating that the market values the company at a premium of 66% over its net asset book value. Alternative valuation metrics include a price-to-sales ratio of 1.59 and an EV/EBITDA of 11.14, suggesting that the market values the firm based on earnings power rather than pure sales volume. The 52-week high is $127.56 and the 52-week low is $62.00, meaning the current price sits within a wide trading range that reflects significant volatility over the past year. The beta value is 0.74, which indicates that the stock price tends to be less volatile than the broader market, moving with lower sensitivity to general market fluctuations.

Growth & Income

Revenue growth for the trailing twelve months was 5.0%, while earnings growth was 52.9%, demonstrating that earnings are expanding at a rate nearly ten times faster than top-line sales. This divergence implies that the company is successfully improving its operational efficiency and profit margins, allowing net income to outpace revenue expansion. The company does not pay a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, indicating that all earnings are retained for reinvestment into growth initiatives, R&D, or debt management. Consequently, the overall growth and income profile for Integer Holdings Corporation is characterized by capital appreciation potential driven by margin expansion rather than current income generation through dividends.

Peer Comparison

Integer Holdings Corporation (ITGR) operates in the Medical Devices industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Integer Holdings Corporation ITGR $3.06B 22.4
Abbott Laboratories ABT $150.96B 24.3
Stryker Corporation SYK $119.99B 36.2
Medtronic plc MDT $99.63B 21.7

The Medical Devices industry average P/E ratio is 60.2x. Integer Holdings Corporation trades at a P/E of 22.4.

This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.

About Integer Holdings Corporation

Integer Holdings Corporation operates as a medical device contract development and manufacturing company in the United States, Costa Rica, Puerto Rico, Ireland, and internationally. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures. It also provides cardiac rhythm management products, including implantable pacemakers, implantable cardioverter defibrillators, insertable cardiac monitors, implantable cardiac pacing and defibrillation leads, and heart failure therapies; implanted medical devices, implanted leads, procedure accessories, and external devices; neuromodulation products, such as implantable spinal cord stimulators; and non-rechargeable batteries, feedthroughs, device enclosures, machined components, and lead components and sub-assemblies. In addition, the company offers rechargeable batteries and chargers; orthopedics, minimally invasive surgery, and general surgery devices; and portable medical devices, including patient monitoring, ventilators, portable defibrillators, portable ultrasound, and X-Ray machines. Furthermore, the company provides medical technologies; supplies medical stamped components, and shallow and deep draw casings and assemblies; and epicardial pacing leads. It serves multi-national original equipment manufacturers and affiliated subsidiaries in the cardiac rhythm management, neuromodulation, orthopedics, cardio and vascular, and advanced surgical and portable medical markets. The company provides its products under the Greatbatch Medical and the Lake Region Medical brands. The company was formerly known as Greatbatch, Inc. and changed its name to Integer Holdings Corporation in July 2016. Integer Holdings Corporation was founded in 1970 and is headquartered in Plano, Texas.

Visit website →

Key Statistics

Market Cap
$3.06B
P/E Ratio
22.37
52-Week High
$123.78
52-Week Low
$62.00
Avg Volume
644.97K
Beta
0.66

Data provided by Yahoo Finance via yfinance. Updated daily.

Company Info

Exchange
NYSE
Country
United States
Employees
11,000